When your science is hard for outsiders to understand, people judge what they can see:

your brand.

Investors, commercial partners, and the scientists you want to hire all judge your capability often without seeing the science itself. We build biotech brands that make the work clear enough to trust and distinct enough to remember.

See our work

The best climate companies stopped leading with climate.

The market moved. The money started going elsewhere. Theword "green" stopped meaning anything. We build brands thatwin on the strength of the technology and the size of theopportunity, with sustainability as the proof.

See the work
Our Perspective
Biotech’s science is complex and, to non-specialists, difficult to distinguish from every other company claiming a breakthrough. We build brands that make scientific breakthrough  credible and visible.

Making a Breakthrough Accessible

An investor can’t see your science in the same way you do. They can’t see interactions happening inside a single cell, or the protein you enhance instead of inhibit. What they can see is your website, your pipeline chart, your fundraising decks, and the complicated illustrations you use to showcase those processes. They’ll judge the science based on those things, because they have no other way in.

Many companies in the category describe their work in the same way, promising to reinvent drug discovery, touting the same abstract helixes and gloved hands. As a standalone platform it can work, but otherwise is indistinguishable from other clinically blue drug discovery startups. Even though your science is different, it disappears.

Our biotech work changes that. iBio came to us running a WordPress site that made a clinical-stage company look years behind its actual science. We rebuilt it so an investor gets the pipeline and the differentiation in one scroll, while a researcher can keep going into the platform detail and real data underneath. BioLoomics needed to explain a platform that screens millions of cells to find the rare few that matter, so we made that single idea, the search for the outlier, the whole identity, instead of reaching for the usual molecules and helixes. Enveda kept one recognizable brand across a seed round, a $51M Series A, and a $130M Series C, so each raise built on the last instead of starting the company's story over from scratch.

None of that is just decoration or a dressing-up of science. For a stranger deciding whether to fund you, join you, partner with you, the brand is the only part of the story they can read from the moment they find you. We help biotech companies make theirs stand out.

Principles for Branding BioTech

Escape biotech visual clichés

Gravely serious blue-to-teal gradients, hexagons, pipette tips shot in shallow focus and microscope-down shots of cells are the default kit for “biotech.” We gave Digital Biology a light-and-dark system drawn from its own idea of shining a light inside the cell.

The fastest way to lose investors is to overclaim

Getting iBio’s copy right meant sitting with their platform scientists, who disagreed openly about how much to put on a public page. The pull was toward putting the mechanism first.

Your best visual is hiding in your own science

Some of the most distinctive biotech brands take their form from drawing (in some cases, literally) on what their science actually does. BioLoomics screens millions of cells to find the handful that produce a working therapeutic antibody, so we built the identity around that search for outliers.

The raise and the brand launch together

A brand that lands with the round gives founders and investors one story to rally behind. Enveda launched ahead of a $51M Series A, with the frameworks we built carrying its fundraising and communications.

One site has to satisfy everyone all at once

Each audience wants something different: pipeline credibility, diligence-grade detail, a reason to leave a stable lab. For Fauna Bio, we built distinct journeys under one brand rather than a single page trying to serve everyone at a third of its strength.

Your science is probably ahead of your brand

Science moves fast, so biotech brands look outdated more quickly. Arpeggio's science outran its identity, so we relaunched the brand with infographics that explain RNA-seq without simplifying it.

Our Biotech Portfolio

Enveda Biosciences

A digital-first company using knowledge graphs, machine learning, and metabolomics to find new small molecules, needing a brand that signaled commercial readiness in addition to scientific ambition in a field with decade-long timelines.
We built a modular identity fusing nature and science (a leaf paired with isometric scientific shapes), launched ahead of the raise, and stayed on as an extension of the team from 2021 to 2024 through a full website redesign.
“Wunderdogs did phenomenal work on our brand... I can only describe it as industrialized creativity.”
Viswa Colluru
CEO, Enveda Biosciences
Brand carried the company from a $4.9M seed through a $51M Series A to a $130M Series C.
Plant-based drug discovery
Case Study

iBio

A clinical-stage company whose WordPress site reflected an earlier chapter; the science had moved well past the brand, and two audiences (investors and scientific partners) were finding a company that looked less advanced than it was.
Web strategy, copy, design, and a full Webflow build, working directly with the science team on how much to say without overclaiming. Layered information architecture: top-line framing for scanners, scientific substance underneath, real platform data, plus IR-site integration.
“We want to fall into the 10% of companies that actually have results, and we can show that.”
Martin Brenner
CEO and CSO, iBio
Antibody discovery
Obesity and cardiometabolic
Case Study

Fauna Bio

A company using genetic data from evolved disease resistance in mammals to find drug targets, outgrowing its Wix site and needing a platform that signaled maturity to investors, pharma partners, and scientific talent.
A relationship that began with fundraising and partnership decks and grew, over three years, into a full Webflow rebuild with distinct user journeys and clear visualization of the Convergence platform and pipeline.
“The team was very responsive... our website rollout went extremely well, and we've had a lot of positive feedback on the site.”
Ashley Zehnder
CEO, Fauna Bio
Evolutionary genomics
AI drug discovery
Case Study
Entact Bio
A new modality that enhances beneficial proteins rather than inhibiting harmful ones. We built an identity from abstract protein-interaction shapes including a logo based on the team's own schematic.
Launched with an $81M Series A in 2022.
Targeted protein enhancement
Think Bioscience
A company that thinks like a living system rather than a computer. We built an identity from nature's logic, a dynamic mosaic and organic forms, setting it apart from peers who retrofit AI for biology.
Grew into an oversubscribed $17M seed round.
Synthetic biology
Small-molecule discovery
Bits in Bio
A nonprofit community connecting software and life-science experts. We built a brand that balanced playfulness with scientific credibility, uniting newcomers and established professionals under one identity.
5,000+ active members across 15+ cities.
Computational biology community
BioLoomics
A full brand and digital build with an identity drawn from the platform's core move, finding the outlier cell, and a split light-and-dark site built to speak to both technical and non-technical readers.
Brand launched alongside an $8.7M round.
Single-cell screening
Single-cell screening
Volta Labs
Full-stack genomic sample prep across hardware, software, chemistry, and biology. We built a look with precision and personality, abstracting the flow of genomic data into clean, animated forms.
Launched alongside a $20M Series A 2022.
Genomic automation
Sample prep

FAQs

How should a biotech company brand itself before a raise?

Treat your brand as part of the raise. A raise is the moment the most people look at you at once (investors, press, recruits, partners), and at that stage they're judging your company with no results yet. Your brand reads as proof of seriousness. A placeholder site reads as the opposite. That's why the strongest launches ship the brand and the round together, the way Entact did with its $81M Series A and Enveda ahead of its $51M.

How do you make deep science credible to investors without overclaiming?

Say less. Prove more. An investor in biotech has likely been pitched by dozens of companies using identical superlatives, so words like “breakthrough” and “revolutionary” carry almost no meaning. Overclaiming backfires. What investors do notice is specific, verifiable substance. Don’t skip it. Restraint with detail reads as confidence-plus-proof. Your brand carries those claims for you.

How do you design a biotech site for investors, partners, and scientific talent at once?

Build distinct journeys under one brand. These readers arrive at different depths and different moments, looking for different information. A single page aimed at all three (investors, partners, scientists) lands in the middle of each, too shallow for the partner, too dense for the scanner. Layering lets each reader choose their own depth, so no one is served at half (or a third) strength.

What’s the most common branding mistake biotech startups make?

Visual clichés. The job of a biotech brand is to make genuinely different science look different. Clichés do the opposite. Using the same cues as everyone else says “generic biotech” in the first second, before a viewer reads a word.

When should a biotech company rebrand?

When the science has outgrown the brand. Biotech companies advance in ways outsiders can’t see (new data, sharper pipelines, more research, a larger claim on the field) while the website sits still, and the gap compounds until the company looks less advanced than it is. As soon as the brand undersells where the science sits, it’s time to refresh. Usually that means keeping the name people already know and rebuilding the parts that are dated (the site, the messaging, the visual system).

Great care deserves a brand people trust on sight.

Contact us